Aspirin (acetylsalicylic acid) has become one of the most commonly used drugs, given its role as an analgesic, antipyretic and agent for cardiovascular prophylaxis. Several decades of research have provided considerable evidence demonstrating its potential for the prevention of cancer, particularly colorectal cancer. Broader clinical recommendations for aspirin-based chemoprevention strategies have recently been established; however, given the known hazards of long-term aspirin use, larger-scale adoption of an aspirin chemoprevention strategy is likely to require improved identification of individuals for whom the protective benefits outweigh the harms. Such a precision medicine approach may emerge through further clarification of aspirin's mechanism of action.
Subscribe to Journal
Get full journal access for 1 year
only $21.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin. 65, 5–29 (2015).
Chan, A. T. et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev. Res. (Phila.) 5, 164–178 (2012).
Thorat, M. A. & Cuzick, J. Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population. Eur. J. Epidemiol. 30, 5–18 (2015).
U.S. Preventive Services Task Force. Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U. S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 146, 361–364 (2007).
U.S. Preventive Services Task Force. Draft Recommendation Statement: Aspirin to prevent cardiovascular disease and cancer U.S. Preventive Services Task Force [online] (2015).
Chubak, J., Kamineni, A., Buist, D. S. M., Anderson, M. L. & Whitlock, E. P. Aspirin Use for the Prevention of Colorectal Cancer: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force (Agency for Healthcare Research and Quality (US), 2015).
Dehmer, S. P., Maciosek, M. V. & Flottemesch, T. J. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: A Decision Analysis: Technical Report (Agency for Healthcare Research and Quality (US), 2015).
Cuzick, J. et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 10, 501–507 (2009).
Flossmann, E. et al. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369, 1603–1613 (2007).
Rothwell, P. M. et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379, 1602–1612 (2012).
Thun, M. J., Jacobs, E. J. & Patrono, C. The role of aspirin in cancer prevention. Nat. Rev. Clin. Oncol. 9, 259–267 (2012).
Nan, H. et al. Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. JAMA 313, 1133–1142 (2015).
Friis, S., Riis, A. H., Erichsen, R., Baron, J. A. & Sorensen, H. T. Low-dose aspirin or nonsteroidal anti-inflammatory drug use and colorectal cancer risk: a population-based, case-control study. Ann. Intern. Med. 163, 347–355 (2015).
Rothwell, P. M. et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376, 1741–1750 (2010).
Sturmer, T. et al. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann. Intern. Med. 128, 713–720 (1998).
Cook, N. R. et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 294, 47–55 (2005).
Burn, J. et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N. Engl. J. Med. 359, 2567–2578 (2008).
Cook, N. R., Lee, I. M., Zhang, S. M., Moorthy, M. V. & Buring, J. E. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann. Intern. Med. 159, 77–85 (2013).
Burn, J. et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomized controlled trial. Lancet 378, 2081–2087 (2011).
Cunningham, J. M. et al. The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am. J. Hum. Genet. 69, 780–790 (2001).
Fearon, E. R. Molecular genetics of colorectal cancer. Annu. Rev. Pathol. 6, 479–507 (2011).
Eide, T. J. Natural history of adenomas. World J. Surg. 15, 3–6 (1991).
Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759–767 (1990).
Morson, B. C. The evolution of colorectal carcinoma. Clin. Radiol. 35, 425–431 (1984).
Neugut, A. I., Johnsen, C. M., Forde, K. A. & Treat, M. R. Recurrence rates for colorectal polyps. Cancer 55, 1586–1589 (1985).
Baron, J. A. et al. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 348, 891–899 (2003).
Sandler, R. S. et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med. 348, 883–890 (2003).
Logan, R. F. et al. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 134, 29–38 (2008).
Benamouzig, R. et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 125, 328–336 (2003).
Ishikawa, H. et al. The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial. Gut 63, 1755–1759 (2014).
Drew, D. A. et al. Colorectal polyp prevention by daily aspirin use is abrogated among active smokers. Cancer Causes Control 27, 93–103 (2015).
Pommergaard, H. C., Burcharth, J., Rosenberg, J. & Raskov, H. Aspirin, calcitriol, and calcium do not prevent adenoma recurrence in a randomized controlled trial. Gastroenterology 150, 114–122 (2015).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00501059 (2015).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00565708 (2015).
ISRCTN Registry. Aspirin in reducing events in the elderly. ISRCTN.orghttp://dx.doi.org/10.1186/ISRCTN83772183 (2015).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02394769 (2015).
ISRCTN Registry. Finding the best dose of aspirin to prevent Lynch Syndrome cancers. ISRCTN.orghttp://dx.doi.org/10.1186/ISRCTN16261285 (2015).
ISRCTN Registry. The seAFOod (Systematic Evaluation of Aspirin and Fish Oil) polyp prevention trial. ISRCTN.orghttp://dx.doi.org/10.1186/ISRCTN05926847 (2015).
Whitlock, E. P., Williams, S.B., Burda, B. U., Feightner, A. & Beil, T. Aspirin Use in Adults: Cancer, All-Cause Mortality, and Harms: A Systematic Evidence Review for the U. S. Preventive Services Task Force. (Agency for Healthcare Research and Quality (US), 2015).
Lanas, A., Wu, P., Medin, J. & Mills, E. J. Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis. Clin. Gastroenterol. Hepatol. 9, 762–768 (2011).
Serebruany, V. L. et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am. J. Cardiol. 95, 1218–1222 (2005).
Derry, S. & Loke, Y. K. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 321, 1183–1187 (2000).
McQuaid, K. R. & Laine, L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am. J. Med. 119, 624–638 (2006).
The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg versus 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N. Engl. J. Med. 325, 1261–1266 (1991).
Farrell, B., Godwin, J., Richards, S. & Warlow, C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J. Neurol. Neurosurg. Psychiatry 54, 1044–1054 (1991).
Roderick, P. J., Wilkes, H. C. & Meade, T. W. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br. J. Clin. Pharmacol. 35, 219–226 (1993).
Weil, J. et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 310, 827–830 (1995).
Ulrich, C. M., Bigler, J. & Potter, J. D. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat. Rev. Cancer 6, 130–140 (2006).
Barry, E. L. et al. CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment. Cancer Causes Control 24, 47–54 (2013).
Chan, A. T., Hsu, M., Zauber, A. G., Hawk, E. T. & Bertagnolli, M. M. The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma. Cancer Prev. Res. (Phila.) 5, 61–72 (2012).
Chan, A. T. et al. Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology 136, 2127–2136 (2009).
McGreavey, L. E. et al. No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARδ and PPARγ act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma. Pharmacogenet. Genom. 15, 713–721 (2005).
Roy, H. K. et al. Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin. Gut http://dx.doi.org/10.1136/gutjnl-2015-309996 (2015).
Thomas, S. S. et al. Tissue-specific patterns of gene expression in the epithelium and stroma of normal colon in healthy individuals in an aspirin intervention trial. BMC Med. Genet. 16, 18 (2015).
Thompson, C. L. et al. No association between cyclooxygenase-2 and uridine diphosphate glucuronosyltransferase 1A6 genetic polymorphisms and colon cancer risk. World J. Gastroenterol. 15, 2240–2244 (2009).
Angstadt, A. Y. et al. The effect of UGT1A and UGT2B polymorphisms on colorectal cancer risk: haplotype associations and gene-environment interactions. Genes Chromosomes Cancer 53, 454–466 (2014).
Scherer, D. et al. Genetic variation in UGT genes modify the associations of NSAIDs with risk of colorectal cancer: colon cancer family registry. Genes Chromosomes Cancer 53, 568–578 (2014).
Garcia-Albeniz, X. & Chan, A. T. Aspirin for the prevention of colorectal cancer. Best Pract. Res. Clin. Gastroenterol. 25, 461–472 (2011).
Hull, M. A. Cyclooxygenase-2: how good is it as a target for cancer chemoprevention? Eur. J. Cancer 41, 1854–1863 (2005).
Patrignani, P. & Patrono, C. Cyclooxygenase inhibitors: from pharmacology to clinical read-outs. Biochim. Biophys. Acta 1851, 422–432 (2015).
Ranger, G. S. Current concepts in colorectal cancer prevention with cyclooxygenase inhibitors. Anticancer Res. 34, 6277–6282 (2014).
Schror, K. Pharmacology and cellular/molecular mechanisms of action of aspirin and non-aspirin NSAIDs in colorectal cancer. Best Pract. Res. Clin. Gastroenterol. 25, 473–484 (2011).
Wang, D. & Dubois, R. N. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 29, 781–788 (2010).
Dixon, D. A., Blanco, F. F., Bruno, A. & Patrignani, P. Mechanistic aspects of COX-2 expression in colorectal neoplasia. Recent Results Cancer Res. 191, 7–37 (2013).
Fink, S. P. et al. Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD). Sci. Transl Med. 6, 233re2 (2014).
Chan, A. T., Ogino, S. & Fuchs, C. S. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N. Engl. J. Med. 356, 2131–2142 (2007).
Elzagheid, A. et al. High cyclooxygenase-2 expression is associated with advanced stages in colorectal cancer. Anticancer Res. 33, 3137–3143 (2013).
Pugh, S. & Thomas, G. A. Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut 35, 675–678 (1994).
Chulada, P. C. et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res. 60, 4705–4708 (2000).
Mutoh, M. et al. Involvement of prostaglandin E receptor subtype EP4 in colon carcinogenesis. Cancer Res. 62, 28–32 (2002).
Oshima, M. et al. Suppression of intestinal polyposis in ApcΔ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87, 803–809 (1996).
Sonoshita, M. et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in ApcΔ716 knockout mice. Nat. Med. 7, 1048–1051 (2001).
Watanabe, K. et al. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res. 59, 5093–5096 (1999).
Nishihara, R. et al. Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA 309, 2563–2571 (2013).
I.Jspeert, J. E., Vermeulen, L., Meijer, G. A. & Dekker, E. Serrated neoplasia-role in colorectal carcinogenesis and clinical implications. Nat. Rev. Gastroenterol. Hepatol. 12, 401–409 (2015).
Kedrin, D. & Gala, M. K. Genetics of the serrated pathway to colorectal cancer. Clin. Transl Gastroenterol. 6, e84 (2015).
Bettington, M. et al. The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology 62, 367–386 (2013).
Myung, S. J. et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc. Natl Acad. Sci. USA 103, 12098–12102 (2006).
Yan, M. et al. 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc. Natl Acad. Sci. USA 106, 9409–9413 (2009).
Guda, K. et al. Inactivating mutation in the prostaglandin transporter gene, SLCO2A1, associated with familial digital clubbing, colon neoplasia, and NSAID resistance. Cancer Prev. Res. (Phila.) 7, 805–812 (2014).
Murphey, L. J. et al. Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal. Biochem. 334, 266–275 (2004).
Wang, D. & DuBois, R. N. Urinary PGE-M: a promising cancer biomarker. Cancer Prev. Res. (Phila.) 6, 507–510 (2013).
Cai, Q. et al. Prospective study of urinary prostaglandin E2 metabolite and colorectal cancer risk. J. Clin. Oncol. 24, 5010–5016 (2006).
Shrubsole, M. J. et al. Urinary prostaglandin E2 metabolite and risk for colorectal adenoma. Cancer Prev. Res. (Phila.) 5, 336–342 (2012).
Johnson, J. C. et al. Urine PGE-M: a metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia. Clin. Gastroenterol. Hepatol. 4, 1358–1365 (2006).
Bezawada, N. et al. Urinary PGE-M levels are associated with risk of colorectal adenomas and chemopreventive response to anti-inflammatory drugs. Cancer Prev. Res. (Phila.) 7, 758–765 (2014).
Fedirko, V. et al. Urinary metabolites of prostanoids and risk of recurrent colorectal adenomas in the Aspirin/Folate Polyp Prevention Study (AFPPS). Cancer Prev. Res. (Phila.) 8, 1061–1068 (2015).
Wang, D. & Dubois, R. N. Eicosanoids and cancer. Nat. Rev. Cancer 10, 181–193 (2010).
Bigler, J. et al. Polymorphisms predicted to alter function in prostaglandin E2 synthase and prostaglandin E2 receptors. Pharmacogenet. Genom. 17, 221–227 (2007).
Liu, W., Poole, E. M., Ulrich, C. M. & Kulmacz, R. J. Decreased cyclooxygenase inhibition by aspirin in polymorphic variants of human prostaglandin H synthase-1. Pharmacogenet. Genom. 22, 525–537 (2012).
Hubner, R. A. et al. Polymorphisms in PTGS1, PTGS2 and IL-10 do not influence colorectal adenoma recurrence in the context of a randomized aspirin intervention trial. Int. J. Cancer 121, 2001–2004 (2007).
Barry, E. L. et al. Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence—data from a randomized clinical trial. Cancer Epidemiol. Biomarkers Prev. 18, 2726–2733 (2009).
Poole, E. M. et al. Genetic variation in prostaglandin E2 synthesis and signaling, prostaglandin dehydrogenase, and the risk of colorectal adenoma. Cancer Epidemiol. Biomarkers Prev. 19, 547–557 (2010).
Resler, A. J. et al. Genetic variation in prostaglandin synthesis and related pathways, NSAID use and colorectal cancer risk in the Colon Cancer Family Registry. Carcinogenesis 35, 2121–2126 (2014).
Fresno Vara, J. A. et al. PI3K/Akt signalling pathway and cancer. Cancer Treat. Rev. 30, 193–204 (2004).
Liao, X. et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N. Engl. J. Med. 367, 1596–1606 (2012).
Prage, E. B. et al. Location of inhibitor binding sites in the human inducible prostaglandin E synthase, MPGES1. Biochemistry 50, 7684–7693 (2011).
Morgenstern, R., Zhang, J. & Johansson, K. Microsomal glutathione transferase 1: mechanism and functional roles. Drug Metab. Rev. 43, 300–306 (2011).
Nakanishi, M., Gokhale, V., Meuillet, E. J. & Rosenberg, D. W. mPGES-1 as a target for cancer suppression: a comprehensive invited review “Phospholipase A2 and lipid mediators”. Biochimie 92, 660–664 (2010).
Kwon, Y. J. et al. Genome-wide analysis of DNA methylation and the gene expression change in lung cancer. J. Thorac. Oncol. 7, 20–33 (2012).
Aoyama, M. et al. LMO3 interacts with neuronal transcription factor, HEN2, and acts as an oncogene in neuroblastoma. Cancer Res. 65, 4587–4597 (2005).
MacDonald, B. T., Tamai, K. & He, X. Wnt/β-catenin signaling: components, mechanisms, and diseases. Dev. Cell 17, 9–26 (2009).
Bos, C. L. et al. Effect of aspirin on the Wnt/β-catenin pathway is mediated via protein phosphatase 2A. Oncogene 25, 6447–6456 (2006).
Gala, M. K. & Chan, A. T. Molecular pathways: aspirin and Wnt signaling—a molecularly targeted approach to cancer prevention and treatment. Clin. Cancer Res. 21, 1543–1548 (2015).
Castellone, M. D., Teramoto, H., Williams, B. O., Druey, K. M. & Gutkind, J. S. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-β-catenin signaling axis. Science 310, 1504–1510 (2005).
Goessling, W. et al. Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell 136, 1136–1147 (2009).
He, T. C., Chan, T. A., Vogelstein, B. & Kinzler, K. W. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99, 335–345 (1999).
Gupta, R. A. et al. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc. Natl Acad. Sci. USA 97, 13275–13280 (2000).
Gupta, R. A. et al. Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-δ accelerates intestinal adenoma growth. Nat. Med. 10, 245–247 (2004).
Wang, D. et al. Prostaglandin E2 promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor δ. Cancer Cell 6, 285–295 (2004).
Ouyang, N., Williams, J. L. & Rigas, B. NO-donating aspirin isomers downregulate peroxisome proliferator-activated receptor (PPAR)δ expression in APCmin/+ mice proportionally to their tumor inhibitory effect: implications for the role of PPARδ in carcinogenesis. Carcinogenesis 27, 232–239 (2006).
Tomlinson, I. et al. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat. Genet. 39, 984–988 (2007).
Zanke, B. W. et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat. Genet. 39, 989–994 (2007).
Pomerantz, M. M. et al. The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat. Genet. 41, 882–884 (2009).
Nan, H. et al. Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations. J. Natl Cancer Inst. 105, 1852–1861 (2013).
Haiman, C. A. et al. A common genetic risk factor for colorectal and prostate cancer. Nat. Genet. 39, 954–956 (2007).
Montrose, D. C. et al. The role of PGE2 in intestinal inflammation and tumorigenesis. Prostaglandins Other Lipid Mediat. 116–117, 26–36 (2015).
Ma, X., Aoki, T., Tsuruyama, T. & Narumiya, S. Definition of prostaglandin E2–EP2 signals in the colon tumor microenvironment that amplify inflammation and tumor growth. Cancer Res. 75, 2822–2832 (2015).
Chan, A. T., Ogino, S., Giovannucci, E. L. & Fuchs, C. S. Inflammatory markers are associated with risk of colorectal cancer and chemopreventative response to anti-inflammatory drugs. Gastroenterology 140, 799–808 (2011).
Song, M. et al. A prospective study of plasma inflammatory markers and risk of colorectal cancer in men. Br. J. Cancer 108, 1891–1898 (2013).
Heikkila, K. et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 20, 15–26 (2009).
Kakourou, A. et al. Interleukin-6 and risk of colorectal cancer: results from the CLUE II cohort and a meta-analysis of prospective studies. Cancer Causes Control 26, 1449–1460 (2015).
Wang, X., Baek, S. J. & Eling, T. E. The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1/GDF15) in cancer. Biochem. Pharmacol. 85, 597–606 (2013).
Breit, S. N. et al. The TGF-β superfamily cytokine, MIC-1/GDF15: a pleotrophic cytokine with roles in inflammation, cancer and metabolism. Growth Factors 29, 187–195 (2011).
Mehta, R. S. et al. A prospective study of macrophage inhibitory cytokine-1 (MIC-1/GDF15) and risk of colorectal cancer. J. Natl Cancer Inst. 106, dju016 (2014).
Smyth, E., Grosser, T. & FitzGerald, G. Goodman & Gillman's The Pharmacological Basis of Therapeutics (McGraw-Hill, 2011).
Dixon, D. A. et al. Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling. J. Clin. Invest. 116, 2727–2738 (2006).
Chan, A. T., Ogino, S. & Fuchs, C. S. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302, 649–658 (2009).
Din, F. V. et al. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut 59, 1670–1679 (2010).
Goh, C. H. et al. Post-operative aspirin use and colorectal cancer-specific survival in patients with stage I–III colorectal cancer. Anticancer Res. 34, 7407–7414 (2014).
Li, P. et al. Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis. Gut 64, 1419–1425 (2015).
Ng, K. et al. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J. Natl Cancer Inst. 107, 345 (2015).
Thun, M. J., Namboodiri, M. M. & Heath, C. W. Jr. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. 325, 1593–1596 (1991).
Algra, A. M. & Rothwell, P. M. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 13, 518–527 (2012).
Rothwell, P. M. et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379, 1591–1601 (2012).
Tougeron, D., Sha, D., Manthravadi, S. & Sinicrope, F. A. Aspirin and colorectal cancer: back to the future. Clin. Cancer Res. 20, 1087–1094 (2014).
Domingo, E. et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J. Clin. Oncol. 31, 4297–4305 (2013).
Reimers, M. S. et al. Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer. JAMA Intern. Med. 174, 732–739 (2014).
Kothari, N. et al. Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation. Acta Oncol. 54, 487–492 (2015).
Ye, X. F., Wang, J., Shi, W. T. & He, J. Relationship between aspirin use after diagnosis of colorectal cancer and patient survival: a meta-analysis of observational studies. Br. J. Cancer 111, 2172–2179 (2014).
ISRCTN Registry. ADD-ASPIRIN: the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. ISRCTN.orghttp://dx.doi.org/10.1186/ISRCTN74358648 (2015).
Roy, H. K. et al. Association between rectal optical signatures and colonic neoplasia: potential applications for screening. Cancer Res. 69, 4476–4483 (2009).
Radosevich, A. J. et al. Rectal optical markers for in vivo risk stratification of premalignant colorectal lesions. Clin. Cancer Res. 21, 4347–4355 (2015).
Liesenfeld, D. B. et al. Aspirin reduces plasma concentrations of the oncometabolite 2-hydroxyglutarate: results of a randomized, double-blind, crossover trial. Cancer Epidemiol. Biomarkers Prev. 25, 180–187 (2015).
Gerner, E. W. & Meyskens, F. L. Jr. Combination chemoprevention for colon cancer targeting polyamine synthesis and inflammation. Clin. Cancer Res. 15, 758–761 (2009).
Casero, R. A. Jr & Marton, L. J. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat. Rev. Drug Discov. 6, 373–390 (2007).
Gerner, E. W. & Meyskens, F. L. Jr. Polyamines and cancer: old molecules, new understanding. Nat. Rev. Cancer 4, 781–792 (2004).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00983580 (2015).
Meyskens, F. L. Jr et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev. Res. (Phila.) 1, 32–38 (2008).
Martinez, M. E. et al. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc. Natl Acad. Sci. USA 100, 7859–7864 (2003).
Barry, E. L. et al. Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention. J. Natl Cancer Inst. 98, 1494–1500 (2006).
Hubner, R. A. et al. Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention. Clin. Cancer Res. 14, 2303–2309 (2008).
Zell, J. A. et al. Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients. J. Natl Cancer Inst. 102, 1513–1516 (2010).
Barry, E. L., Mott, L. A., Sandler, R. S., Ahnen, D. J. & Baron, J. A. Variants downstream of the ornithine decarboxylase gene influence risk of colorectal adenoma and aspirin chemoprevention. Cancer Prev. Res. (Phila.) 4, 2072–2082 (2011).
Wender, R. C. Aspirin and NSAID chemoprevention, gene-environment interactions, and risk of colorectal cancer. JAMA 313, 1111–1112 (2015).
Hull, M. A. et al. A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trial. Trials 14, 237 (2013).
Baron, J. A. et al. Gastrointestinal adverse effects of short-term aspirin use: a meta-analysis of published randomized controlled trials. Drugs R D 13, 9–16 (2013).
Abraham, N. S. et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am. J. Gastroenterol. 105, 2533–2549 (2010).
Fuster, V. & Sweeny, J. M. Aspirin: a historical and contemporary therapeutic overview. Circulation 123, 768–778 (2011).
Vane, J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 231, 232–235 (1971).
Kune, G. A., Kune, S. & Watson, L. F. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res. 48, 4399–4404 (1988).
Vogelstein, B. et al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319, 525–532 (1988).
Giovannucci, E. et al. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann. Intern. Med. 121, 241–246 (1994).
Giovannucci, E. et al. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med. 333, 609–614 (1995).
Cole, B. F. et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J. Natl Cancer Inst. 101, 256–266 (2009).
A.T.C. has previously served as a consultant for Bayer Healthcare, Millennium Pharmaceuticals, Pfizer Inc. and Pozen Inc. This study was not funded by Bayer Healthcare, Millennium Pharmaceuticals, Pfizer Inc. or Pozen Inc. D.A.D. and Y.C. declare no competing interests.
- Case–control studies
A type of observational study design in which two groups differ according to outcome (for example, in which those with the disease or condition (cases) are compared with disease-free individuals (controls)). These studies can be nested within a larger cohort with only a subset of the larger control population being used.
- Confidence interval
(CI). A measure of the uncertainty associated with a sample estimate for a given parameter.
- Events per 1,000 person-years
Also known as the incidence density rate or person–time incidence rate. This approach normalizes event observations to the amount of observation time and is useful if observation times are not constant across a sample population or the risk of an event varies over time.
- Fractal dimension
(FRAC). A spectroscopic measure of light scattering due to nanoscale architectural changes in mass density of cellular components that has been associated with early neoplastic changes in epithelial cells.
The addition of glucuronic acid to a substrate.
- H2 blocker
A drug that inhibits the production of gastric acid by targeting histamine H2 receptors of gastric parietal cells.
- Hazard ratio
(HR). A measure of the ratio of the hazard rates (the rate at which an event occurs) for a given outcome (for example, cancer) described by an explanatory variable (for example, aspirin versus placebo).
- Incidence rate ratio
(IRR). A measure of the ratio between the rates of how often an outcome (for example, cancer) occurs in a population at any given time according to an explanatory variable (for example, aspirin versus placebo).
- Odds ratio
(OR). A measure of association representing the odds (the probability of disease divided by 1 minus the probability) of an outcome according to an explanatory variable (for example, aspirin users versus non-users).
- P heterogeneity
A statistic that measures the significance of the difference (or heterogeneity) between two effect sizes.
- P interaction
A statistic that measures the significance of the effect of a given exposure or explanatory variable on a second exposure or explanatory variable, and vice versa.
- Proton pump inhibitor
A drug that inhibits the production of gastric acid by targeting the proton pump transport activity of gastric parietal cells. Proton pump inhibitors are generally more effective than H2 blockers.
- P trend
A statistic that measures the significance of a correlation of effect size, either positive or negative, across a continuous or ordinal variable.
- Relative risk
(RR). The probability of an outcome (for example, cancer) occurring in one group (for example, aspirin) versus the probability in a comparison group (for example, placebo).
- Serrated carcinogenesis pathway
A carcinogenesis pathway in which colorectal tumours are characterized by epigenetic dysregulation (promoter hypermethylation), BRAF mutation and activation, and often microsatellite instability, rather than adenomatous polyposis coli (APC) mutations and chromosomal instability.
- Single nucleotide polymorphism
(SNP). A common type of genetic variation in which a single nucleotide or base occurs at a specific position in the genome that is different from the expected or reference nucleotide.
- Spectral slope
(SPEC). A spectroscopic measure of light scattering due to nanoscale architectural changes in the size distribution of cellular components that has been associated with early neoplastic changes in epithelial cells.
About this article
Cite this article
Drew, D., Cao, Y. & Chan, A. Aspirin and colorectal cancer: the promise of precision chemoprevention. Nat Rev Cancer 16, 173–186 (2016). https://doi.org/10.1038/nrc.2016.4
Concurrent Aspirin Use Is Associated with Improved Outcome in Rectal Cancer Patients Who Undergo Chemoradiation Therapy
Annual Review of Medicine (2021)
JAMA Oncology (2021)
Associations between daily aspirin use and cancer risk across strata of major cancer risk factors in two large U.S. cohorts
Cancer Causes & Control (2021)